Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

Bernard Zinman, Greg Fulcher, Paturi Vishnupriya Rao, Nihal Thomas, Lars Endahl, Thue Johansen, Rebecka Lindh, Andrew Lewin, Julio Rosenstock, M. Pinget,

The Lancet · 2011 · 131 citations · 13 references

Concepts

References

13